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Abstract
Background: The adipokine leptin regulates energy expenditure, vascular function, bone and cartilage growth as
well as the immune system and systemic inflammatory response. Several activating effects towards T cells,
monocytes, endothelium cells and cytokine production have been reported suggesting a protective role of leptin in
the setting of an acute systemic inflammation. However, the pathophysiological role of leptin during severe sepsis
is currently not elucidated in detail. This study aims to investigate leptin expression in cultured human adipocytes
within an inflammatory model and in patients suffering from severe sepsis and evaluates treatment effects of
drotrecogin alpha (activated) (DAA), the recombinant form of human activated protein C.
Methods: In an in-vitro inflammatory model of adipocyte cell-culture the effect of DAA on leptin mRNA expression
was evaluated. Synthesis of mRNA was measured by quantitative polymerase chain reaction (qPCR). Additionally,
supernatants of these adipocytes as well as serum levels of adiponectin were measured in blood of 104 severe
septic patients by ELISA-method. 26 patients were treated with DAA (DAA+), 78 patients were not treated with
DAA (DAA-).
Results: Stimulation of human adipocytes with TNF alpha over 6 and 24 hours resulted in a significant decrease by
46% and 59% of leptin mRNA transcripts compared to un-stimulated controls (p < 0.05). Leptin levels of
supernatants of adipocyte culture decreased by 25% and 23% (p < 0.05) after incubation with TNF alpha after 6 and
24 hours. Incubation with DAA at 50 ng/ml DAA and 5 μg/ml doubled mRNA expression significantly at 24 hours
(p < 0.05) but not at 6 hours. From day 1 to day 3 of sepsis, leptin levels increased in DAA+ compared to DAA-
patients (p<0.10).
Conclusions: Leptin appears to be involved in the pathogenesis of a systemic inflammatory response during sepsis.
Administration of DAA significantly increased leptin expression. The specific mechanism or even benefit of DAA
towards leptin needs further ongoing research.
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Background
Leptin belongs to the so-called adipokines, hormones
being secreted in adipocytes of white adipose tissue
[1]. Leptin interacts with specific ob-receptors and
reveals pleiotropic neurohumoral functions, which
regulate appetite and energy expenditure via the
hypothalamic-pituitary-adrenal axis, vascular function,
bone and cartilage growth, pregnancy as well as the
regulation of the immune system and systemic inflam-
matory response [2]. Several activating effects towards
T cells, monocytes, endothelium cells and cytokine
production have been reported and might suggest both
a pro-inflammatory and protective role for leptin in
the setting of an acute systemic inflammation [3,4].
Sepsis is defined as a clinical syndrome including an
infection and the systemic inflammatory response [5,6].
Because of its high incidence, mortality rate and asso-
ciated costs within the healthcare system sepsis has be-
come a major challenge of today´s medicine [7,8]. Sepsis
emerges to severe sepsis when one or more organ
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dysfunctions reemerge. Individual factors (eg, genetic
factors or premorbid health status), extent of infection,
and complicating organ dysfunction have a substantial
impact on the disease process. Several inflammatory and
procoagulant markers have been identified indicating the
disease severity in these patients (eg, procalcitonin
(PCT), interleukin 6 (IL-6), D-dimer) [5,6,9].
However, the role of leptin during sepsis is not yet
fully elucidated. Conflicting results have been reported
in which leptin was supposed to be either up- or down-
regulated or even unchanged during systemic inflammation
[10-13]. In addition to its predominant role in the inhib-
ition of blood coagulation, human activated protein C
(APC) plays an important role in the regulation of inflam-
mation [14]. Multiple biological activities of APC have been
demonstrated both in clinical and experimental settings,
comprising pro-fibrinolytic, immune-modulating and anti-
apoptotic properties [15-21]. Drotrecogin alpha (activated)
(DAA) is the recombinant form of human activated protein
C which was administered patients in our intensive care
unit. Therefore we additionally analysed DAA in our in-
flammatory cell model for possible modulatory effects on
leptin levels.
This study aims to investigate the expression of leptin
both – in-vitro – in human adipocyte cell-culture within an
inflammatory model and – in vivo – in patients suffering
from severe sepsis, thereby additionally evaluating the spe-
cific treatment effect of drotrecogin alpha (activated)
(DAA) on leptin expression.
Methods
Cell culture of human adipocytes
Cryopreserved Human White Preadipocytes (HWP)
from subcutaneous adipose tissue and all culture media
were supplied by Promocell (Heidelberg, Germany).
They were cultivated as described by Promocell at 37°C in
a humidified atmosphere of 95% air / 5% CO2. Medium
was changed every 2–3 days. Preadipocytes were plated at
a density of 5000 cells/cm [2] and cultured to total con-
fluency stage in 6-well plates with 3 mL growth medium
without antibiotics, containing 5% fetal calf serum.
Growth medium was replaced and differentiation medium
(including d-Biotin 8 μg/mL, Insulin 0.5 μg/mL, Dexa-
methasone 400 pg/ml, IBMX 44 μg/mL, L-Thyroxine
9 pg/ml, Ciglitazone 3 μg/mL) was added for 72 h to start
the differentiation process. To complete differentiation the
cells were then cultured for further 12 days with adipocyte
nutrition medium (including fetal calf serum 3%, d-Biotin
8 μg/mL, Insulin 0.5 μg/mL, Dexamethasone 400 pg/ml).
During this time lipid droplets developed. Fully differen-
tiated cells at day 15 after starting the differentiation
process were preincubated with 1 mL nutrition medium
lacking fetal calf serum and Dexamethasone for 24 h be-
fore starting the experiment. The dosages of TNF alpha
and DAA used for the present analyses accorded to our
established protocols within our working group, which
have formerly been published, respectively in an inflam-
matory model with endothelial cells [20,21]. Several
dosages of the highly selective and efficient stimulator
TNF alpha resulted in 1 ng/ml as a concentration leading
to sub-maximal effects on cytokines like IL-8 or IL-6. Dro-
trecogin alpha (activated) was added to yield final concen-
trations of 50 ng/ml and 5 μg/ml. 1 h later TNF alpha was
accordingly added for 1 ng/ml. Cells were incubated for
6 h and 24 h and harvested to prepare total RNA. Super-
natants of cell medium were frozen for quantification of
leptin by ELISA. Treatment with DAA (50 ng/ml or 5 μg/
ml) and TNF alpha (1 ng/ml) did not affect adipocyte via-
bility, as assessed by trypan blue exclusion (90% vi-
able cells, no difference to untreated controls).
mRNA expression of leptin
For quantitative evaluation of DAA-dependent leptin
mRNA steady-state expression in adipocyte cultures,
total RNA was prepared by using the RNeasy mini column
kit (Qiagen, Hilden, Germany), including DNAse treat-
ment. Three micrograms of RNA were reverse transcribed
and converted to cDNA with oligo(dT)15 primers using
AMV reverse transcriptase according to standard proto-
cols (Roche Applied Science, Germany, AMV Cat. No.
11495062001). The cDNA was amplified by quantitative
PCR (qPCR) on the ABI 7000 realtime system (Applied
Biosystems, Foster City, USA) using a qPCR-mix with hot
start Taq DNA polymerase, SYBR-Green and enzyme sys-
tem which reduces carryover DNA contamination (SYBRW
GreenER™, Invitrogen, Cat.No.11760500) in the presence
of sense and antisense primers (400 nM each). The sense-
and antisense-primers for leptin were supplied from
SABiosciences Corp. (Cat. No. PPH00581A). GAPDH as
housekeeping gene was analyzed using primers as follows:
[22] sense 5‘-TGCACCACCAACTGCTTAGC-3‘, anti-
sense 5‘-GGCATGGACTGTGGTCATGAG-3‘. The qPCR
condition consisted of 50°C for 2 min (reduction of DNA
carryover contamination), 95°C for 10 min followed by
40 cycles of 95°C for 15 sec and 60°C for 1 min, followed
by melting-curve analysis to verify the correctness of the
amplicon. Relative quantification of leptin mRNA expres-
sion was calculated as follows: The expression of leptin
mRNA relative to the housekeeping gene GAPDH in sam-
ples from cells treated with DAA or untreated (Control)
was calculated by the ΔΔCT method, based on the thresh-
old cycle (CT), as fold change= 2−Δ(ΔCT), where ΔCT=
CTleptin−CTGAPDH and Δ(ΔCT)=ΔCTDAA−ΔCT Control
[23,24]. Efficiencies of the amplification reactions were cal-
culated with a typical sample analysing the slope of the re-
gression line of a 10-fold dilution series of cDNA (log10)
versus CT: Efficiency =10-1/slope. Only primer pairs that
showed an amplification efficiency between 1.90 – 2.05
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(90 –105%) and a coefficient of correlation (r) between
0.90 – 1.0 were used for quantification [25]. For verifica-
tion of the correct length of amplification products, they
were analysed on an ethidium bromide stained 2% agarose
gel. All cell-culture experiments have been repeated at
least twice to guarantee repeatability.
Study population
A total of 104 patients suffering from severe sepsis
were prospectively enrolled at the First Department of
Medicine, University Medical Centre Mannheim (UMM)
(Germany) and at the Department of Anaesthesiology
and Intensive Care Medicine, University Hospital Bonn
(Germany) from March 2001 until October 2006. The
study was carried out according to the principles of the
declaration of Helsinki and was approved by the medical
ethics commission II of the Medical Faculty Mannheim,
University of Heidelberg, Germany. Written informed
consent was obtained from all participating patients or
their legal representatives.
The diagnosis of severe sepsis was based on criteria
established by the American College of Chest Physi-
cians and the Society of Critical Care Medicine
Consensus Conference 1992: [5] Patients presented
with a proven infection, three or more criteria of the
systemic inflammatory response syndrome (SIRS cri-
teria) and at least 1 of the following newly developed,
sepsis-induced organ failures: cardiovascular organ failure
with need for vasopressors, pulmonary organ failure
defined as PaO2/FiO2 <250, renal organ failure with urine
output <0,5 ml/kg/h, hematological organ failure with
platelet count <80000/mm [3] or an unexplained meta-
bolic acidosis with pH <7.3 and lactate levels >1.5 times of
the upper limit of normal. Sepsis-induced organ failures in
these patients were strongly connected to infection and
were present for less than 24 h. Severity of sepsis was
defined by the Acute Physiology and Chronic Health
Evaluation II (APACHE II) score [26].
Out of a total of 104 patients suffering from severe
sepsis 26 patients were treated with drotrecogin alpha
(activated) (DAA) and 78 patients were not treated. The
decision to treat patients with DAA or without was
based on site-specific treatment modalities concerning
the inclusion and exclusion criteria for the administra-
tion of DAA [27]. Twenty-six septic patients received
a 96-hour infusion of DAA (XIGRISW: 24 μg per 1 kg
body weight per hour). 78 patients with severe sepsis did
not receive DAA because of contraindications for
drotrecogin alpha (activated) such as platelet count
30000/mm, need for therapeutic anticoagulation with
heparin, increased risk of bleeding, recent gastrointes-
tinal bleeding, or stroke within the last 3 months
[28]. Additionally 45 healthy humans were included
to serve as a control group.
Baseline characteristics, such as APACHE II scores,
body mass index (BMI), creatinine levels, white blood
cell count, platelet count, C-reactive protein (CRP), bili-
rubin, international normalized ratio (INR), activated
partial thromboplastin time (a-PTT), antithrombin III
(AT III), D-dimer as well as body temperature were
determined on day 1 of severe sepsis. Total clinical
follow-up lasted over 28 days and defined clinical out-
comes such as death or survival were documented.
Plasma samples and leptin assay
Blood samples were obtained by venipuncture into
serum monovettesW within the first 24 h after the diag-
nosis of severe sepsis (day 1), as well as on day 3 and 5
of severe sepsis. Within 30 minutes all blood samples
were centrifuged at 1000 x g at 4°C for 15 minutes.
Serum was separated, frozen and stored at −80°C.
Leptin measurement was performed with a solid
phase two-site immunosorbent assay (ELISA) (Quanti-
kineW human leptin immunoassay, R&D Systems Inc.,
Minneapolis, USA) [29].
Statistical analysis
For data with normal distribution, the Student t test was
applied. Otherwise, the Mann–Whitney U test was used
as a nonparametric test. Deviations from a Gaussian dis-
tribution were tested by the Kolmogorov-Smirnov test.
To generate hypotheses we used multiple t-tests with
Holm-Bonferroni adjustments. For cell culture experi-
ments the most important groups were specified in ad-
vance to be compared by statistical analysis: i) Control
versus TNF alpha; ii) TNF alpha versus TNF alpha +
DAA 50 ng/mL; iii) TNF alpha +DAA 50 ng/mL versus
TNF alpha +DAA 5 μg/mL. Pearson’s correlation was
used for normally distributed data. Spearman’s rank
correlation was used for nonparametric data. Non-
continuous variables were analyzed by the use of a 2x2
table and Fisher’s exact test. Data are presented as
mean ± standard deviation (SD) or standard error of
mean (SEM) as indicated. Values of P < 0.10 (two-tailed)
were considered tending to be significant and P < 0.05
(two-tailed) were considered statistically significant. The
calculations were performed with InStat (GraphPad Soft-
ware) and SPSS software (SPSS Software GmbH).
Results
In-vitro results
In-vitro analyses showed final cell differentiation of
human adipocytes after 15 days of cell growth
(Figure 1a-c). Stimulating human adipocytes with tumor
necrosis factor alpha alone (concentration TNF alpha,
1 ng/ml) over 6 hours resulted in leptin mRNA tran-
scripts decreased by 46% compared to un-stimulated
controls (p < 0.05) (Figure 2). Adding DAA at 50 ng/ml
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Figure 1 Confluent cultures of undifferentiated preadipocytes (a) and mature adipocytes after differentiation for 15 days (b,c). The
high amount of fat droplets, visible as light globules (b,c), demonstrates the cells being differentiated to mature adipocytes. Cells were
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Figure 2 Leptin mRNA expression was significantly decreased after 6 and 24 hours of stimulation with 1 ng/ml TNF alpha (p< 0.05) in
human adipocytes. Drotrecogin alpha (activated) (DAA) dose-dependently increased leptin mRNA levels after 24 hours from DAA 50 ng/ml to
DAA 5 μg/ml (p < 0.05), but at 6 hours no significant change could be detected. Significances (n.s. = not significant) of t-tests with Holm-
Bonferroni adjustments for multiple comparisons are indicated. Only the relevant in advance specified group comparisons were analysed. Data
are presented as mean with standard error of mean (SEM).
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or 5 μg/ml to TNF alpha at 1 ng/ml, a significant change
of leptin mRNA expression could not be detected
(Figure 2). Stimulating human adipocytes with TNF alpha
alone at the same concentration of 1 ng/ml for a longer
time of 24 hours resulted in leptin mRNA transcripts
decreased by 59% compared to un-stimulated controls
(p < 0.05) (Figure 2). Adding DAA at 50 ng/ml or 5 μg/ml
to TNF alpha at 1 ng/ml, a significant upregulation of lep-
tin mRNA expression was detected after 24 hours from
DAA at 50 ng/ml to 5 μg/ml (p < 0.05) (Figure 2).
Similar expression profiles as with leptin mRNA were
seen when measuring leptin levels out of supernatants of
the adipocytes by ELISA. Leptin levels of supernatants of
adipocyte culture decreased by 25% (p < 0.05) after incu-
bation with TNF alpha alone after 6 hours (Figure 3).
After 6 hours incubation with TNF alpha at 1 ng/ml and
DAA at 50 ng/ml or 5 μg/ml leptin levels increased from
DAA at 50 ng/ml to 5 μg/ml (p < 0.05) (Figure 3). After
24 hours leptin levels significantly decreased by 23%
after incubation withTNF alpha alone (p < 0.05) (Figure 3).
But a significant change of leptin levels from DAA at
50 ng/ml to 5 μg/ml could not be detected after 24 hours
(Figure 3).
Treatment with DAA (50 ng/ml or 5 μg/ml) and TNF
alpha (1 ng/ml) did not affect adipocyte viability, as
assessed by trypan blue exclusion (90% viable cells, no
difference to untreated controls; data not shown).
In-vivo results
Baseline characteristics of 104 patients suffering from se-
vere sepsis are given in Table 1. Mean age of all study
patients was 64 years. Patients treated with DAA
(n = 26) were younger than patients not treated (n = 78)
(57 years vs. 67 years; p = 0.002). The most common pri-
mary site of infection was the lung (n = 51), followed by
cardiac (n = 12) and intra-abdominal infections (n = 7)
(p = 0.3). The mean APACHE II score was 28.3 (SD=
5.4). Mean BMI levels were similar in all patient groups
(DAA+, mean = 25.2, ±SEM=2.5, DAA-, mean = 26.6,
±SEM=0.9, p = 0.6).
Leptin serum levels significantly correlated with age,
body temperature, BMI and APACHE II score. Addition-
ally leptin levels inversely correlated with adiponectin,
and correlated positively with white blood cells, antith-
rombin III, interleukin 6 and creatinine (Table 2). How-
ever, there were no significant differences of leptin levels
in patients with impaired renal function (defined as a
serum creatinine value above 1.1 mg/dl) compared to
patients with a regular renal function (defined as a
serum creatinine value below or equal than 1.1 mg/dl)
(patients with renal failure, leptin mean 29282 pg/ml, ±
SEM 4398 pg/ml, n = 75; patients without renal failure,
leptin mean 21896 pg/ml, ± 5631 pg/ml, n = 29; p = 0.3).
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Figure 3 Leptin levels out of supernatants of the adipocytes cell culture measured by ELISA showed decreased levels of leptin after
incubation with TNF alpha for 6 and 24 hours (p < 0.05). Increasing levels of leptin were observed after 6 hours of incubation according to
the applied dosages of DAA (50 ng/ml and 5 μg/ml). Significances (n.s. = not significant) of t-tests with Holm-Bonferroni adjustments for multiple
comparisons are indicated. Only the relevant in advance specified group comparisons were analysed. Data are presented as mean with standard
error of mean (SEM).
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Age (years)* 64.0 ± 13.5 56.6 ± 15.0 66.5 ± 12.1 0.002
Gender (n)
Male 62 16 46 0.8
Female 42 10 32
Body mass index (BMI) * 26.4 ± 0.8 25.2 ± 2.5 26.6 ± 0.9 0.6
Heart rate (beats/min) * 84 ± 23.6 85 ± 20.8 84 ± 24.5 0.76
APACHE II score * 28.3 ± 5.4 28.6 ± 6.5 28.1 ± 5.0 0.9
Primary site of infection (n)
Lung 51 10 41
Urinary 6 2 4
Cerebral 5 2 3
Cardiac 12 4 8 0.3
Intra-abdominal 7 - 7
Skin 2 - 2
Unknown 21 8 13
CRP (mg/l)* 164 ± 126 206 ± 151 151 ± 115 0.2
Creatinine (mg/dl)* 2.6 ± 2.1 3.0 ± 2.3 2.5 ± 2.0 0.2
White blood cells (109/l)* 16.4 ± 8.0 16.0 ± 9.7 16.5 ± 7.5 0.4
Platelets (109/l)* 210 ± 117 202 ± 115 213 ± 118 0.5
aPTT (sec)* 40.7 ± 24.4 42.2 ± 25.5 40.2 ± 24.2 0.4
Antithrombin III (%)* 63.5 ± 19.5 61.4 ± 17.1 64.3 ± 20.6 0.8
D-dimer (μg/ml)* 5.0 ± 3.8 3.0 ± 2.0 5.5 ± 4.1 0.4
Bilirubin (mg/dl)* 1.7 ± 1.8 2.6 ± 2.3 1.4 ± 1.5 0.04
Death (n) 53 17 36 0.9
* Data are presented as mean ± standard deviation (SD).
† p values are calculated for the comparison between DAA+ patients with DAA- patients.
Table 2 Correlations between leptin levels and clinical indices at day 1 of severe sepsis
All patients (n = 104) DAA (n = 26) No DAA(n= 78)
r p-value r p-value r p-value
Age 0.25 0.01 0.34 0.09 0.26 0.02
Body temperature 0.27 0.007 0.57 0.005 0.28 0.02
Body mass index (BMI) 0.40 0.01 0.49 0.4 0.41 0.01
APACHE II score 0.28 0.03 0.34 0.15 0.32 0.04
Adiponectin −0.28 0.04 −0.26 0.19 −0.33 0.003
White blood cell count 0.19 0.06 −0.14 0.52 0.20 0.08
CRP −0.06 0.57 0.15 0.49 −0.09 0.46
Interleukin 6 −0.09 0.37 0.53 0.009 −0.02 0.88
Hemoglobin 0.19 0.06 0.44 0.03 0.12 0.28
Hematocrit 0.20 0.04 0.46 0.02 0.15 0.20
Platelets 0.21 0.03 0.16 0.4 0.15 0.18
Creatinine 0.22 0.03 0.12 0.6 0.32 0.005
Antithrombin III 0.31 0.03 0.6 0.02 0.35 0.04
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As demonstrated in Figure 4, patients suffering from
severe sepsis without treatment of DAA revealed signifi-
cantly higher serum concentrations of leptin compared
to healthy controls (n = 45, mean = 12116 pg/ml, ±
SEM=1945 pg/ml) (leptin concentrations, Day 1: DAA-,
mean = 30175 pg/ml, ±SEM=4203 pg/ml. Day 3: DAA-,
mean = 32670 pg/ml, ± SEM=6173 pg/ml. Day 5: DAA-,
mean = 32731 pg/ml, ±SEM=6220 pg/ml) (p < 0.05).
At the beginning of treatment with DAA (day 1) leptin
levels showed a tendency (p < 0.10) to be lower (day 1:
DAA+, mean = 18991 pg/ml, ±SEM=6009 pg/ml, nc =
26) compared to patients without DAA (Figure 4). From
day 1 to day 3 of sepsis, leptin levels increased in patients
treated with DAA compared to patients without treatment
of DAA (p< 0.10) (leptin concentrations, Day 1: DAA+,
mean=18991 pg/ml, ±SEM=6009 pg/ml. Day 3: DAA+,
mean=57315 pg/ml, ± SEM=17075 pg/ml. Day 5: DAA+,
mean=54980 pg/ml, ±SEM=17660 pg/ml).
There was no difference of leptin concentrations between
patients surviving 28 days follow-up (mean=26073 pg/ml,
±SEM=4704 pg/ml, n=51) compared to those who were
deceased (mean=28824 pg/ml, ±SEM=5442 pg/ml,
n=53) (p> 0.10).
Discussion
This study investigated the expression of leptin both –
in vitro – within an inflammatory model of human cultured
adipocytes and – in vivo – in patients suffering from severe
sepsis and additionally evaluated the specific treatment
effect of drotrecogin alpha (activated) (DAA).
Leptin mRNA and protein expression was down-
regulated by TNF alpha after 6 and 24 hours of incubation
in human adipocytes. But this effect seems not to be due to
a reduced number of viable cells because of TNF alpha
treatment: Treatment with DAA (50 ng/ml or 5 μg/ml) and
TNF alpha (1 ng/ml) did not affect adipocyte viability, as
assessed by trypan blue exclusion. Moreover, administration
of DAA (50 ng/ml or 5 μg/ml) in the presence of TNF
alpha (1 ng/ml) up-regulated leptin mRNA and protein ex-
pression in a dose dependent way at 24 hours. In patients
suffering from severe sepsis leptin serum levels remained at
the same level from days 1 to 5 in those patients without
treatment of DAA. However, in patients treated with
DAA leptin serum levels increased from day 1 to day
3 day of severe sepsis during the infusion of DAA over
96 hours. Leptin serum levels were inversely correlated
with adiponectin and positively correlated with APACHE
II score, body temperature, white blood cell count and
interleukin 6.
The present analysis confirmed preliminary reports
demonstrating decreased mRNA expression of leptin
following TNF alpha stimulation within an in-vitro
inflammatory model [30-34]. However, conflicting
results have been obtained from cell cultures demon-
strating an up-regulation of leptin mRNA expression
after stimulation with TNF alpha [35,36]. These var-
ieties might in part be explained by the use of differ-
ent cell species, anatomical localization of the fat
tissue and the duration of exposure to the stimulating
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Figure 4 Treating patients with DAA resulted in an increase in leptin levels after 96 hours of DAA infusion compared to patients without
treatment of DAA from day 1 to day 3 and 5 (p<0.05) (leptin concentrations, Day 1: DAA+, mean=18991 pg/ml, ±SEM=6009 pg/ml. Day 3:
DAA+, mean=57315 pg/ml, ± SEM=17075 pg/ml. Day 5: DAA+, mean=54980 pg/ml, ±SEM=17660 pg/ml). Significances of t-tests with
Holm-Bonferroni adjustments for multiple comparisons are indicated, otherwise no significance could be reached. Data are presented as mean
with standard error of mean (SEM). * p < 0.10, ** p < 0.05.
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more down-regulated after longer incubation of
24 hours compared to 6 hours (59% vs. 46%).
In accordance with recently published data we could
demonstrate increasing levels of leptin in patients suffer-
ing from severe sepsis compared to healthy controls
[11,37-41] and showed several correlations with estab-
lished clinical markers of sepsis. Therefore our observa-
tions support evidence that leptin appears to be involved
in the pathogenesis and the course of a systemic inflam-
matory response during sepsis. Interestingly, with regard
to the body of literature it was shown that leptin itself
increases the production of TNF alpha or Interleukin 6
from macrophages [42].
DAA has been shown to reveal antithrombotic, profi-
brinolytic, anti-inflammatory and antiapoptotic proper-
ties [27,28]. However, no data currently exist, whether
DAA influences the release of the adipokine leptin. To
the best of our knowledge this study is the first to inves-
tigate the influence of DAA on leptin expression. It
could have been demonstrated that administration of
DAA increases the amount of leptin mRNA and protein
expression over time in human adipocytes and further-
more significantly increases leptin serum levels in
patients suffering from severe sepsis after 96 hours ad-
ministration of DAA.
Therefore, the present findings might reveal another
effect of DAA during sepsis, i.e. the up-regulation of
the hormone leptin under circumstances of ongoing
systemic inflammation. Several in-vitro studies already
demonstrated specific anti-inflammatory effects of
DAA, e.g. inhibition of transcription factor NF-kappa B
in isolated mononuclear cells or the inhibition of
macrophage inflammatory protein-1 (MIP-1-alpha),
monocyte chemoattractant protein-1 (MCP-1), neop-
terin [19,43,44] or up-regulation of adiponectin [45].
However, the role of specifically leptin during severe
sepsis is not yet completely understood. It could have
been demonstrated that patients surviving an acute sep-
sis revealed increased levels of leptin, whereas leptin
correlated with the disease severity and is an independ-
ent predictor of death [37,38,41]. Shapiro et al. [46]
postulated that leptin might be able to pronounce
endothelial dysfunction during sepsis and therefore
worsens outcome of the disease. However, increases of
the soluble leptin receptor (sLR) were explained as a
compensatory anti-inflammatory mechanism.
Limitations
The exact mechanisms contributing to increased leptin
mRNA and protein expressions after administration of
DAA in human adipocytes and patients suffering from
severe sepsis were not determined in this study. How-
ever, we performed cell culture experiments with adipo-
cytes in order to confirm our clinical findings in septic
patients with a more straightforward system and proving
the involvement of adipocytes. Instead of LPS we used
TNF alpha as a more selective and efficient pro-
inflammatory stimulus for sepsis according to our estab-
lished protocols, respectively in an inflammatory model
with endothelial cells having been published already
[20,21]. It was our intention to apply the same condi-
tions as in the above mentioned inflammatory models in
order to guarantee comparability of our own experimen-
tal approach. However, TNF alpha serum levels were not
measured in our septic patients. Regarding clinical bene-
fits of septic patients increased leptin levels could not
show a survival benefit over 28-days follow-up in our
study. Nevertheless, our results need to be confirmed by
ongoing basic research analyses and larger prospective
clinical studies to explain the more detailed mechanisms
beyond our findings.
Conclusions
Taken together, it has been demonstrated that leptin
mRNA and -protein expression is down-regulated by
TNF alpha in human adipocytes. Administration of
DAA up-regulated leptin expression over time and in-
creasing applied dosages of DAA. Accordingly, patients
suffering from severe sepsis revealed increased leptin
serum levels, while patients treated with DAA revealed
increasing leptin serum levels after complete treatment
with DAA (i.e. 96 hours infusion) at day 3 and 5 com-
pared to untreated septic patients. Therefore, our results
support the hypothesis that leptin might be involved in
the pathogenesis of a systemic inflammatory response
during sepsis possibly acting as an anti-inflammatory pro-
tein. The specific mechanism or even benefit of DAA ad-
ministration in the time course of sepsis towards leptin
needs further ongoing research.
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